Adjunctive pharmacological strategies for residual risk reduction after myocardial revascularisation - PubMed
5 days ago
- #cardiovascular disease
- #pharmacological treatment
- #residual risk
- Pharmacological treatment is crucial for managing atherosclerotic cardiovascular disease (ASCVD).
- LDL cholesterol-lowering therapies, including statins, ezetimibe, bempedoic acid, and PCSK9 inhibitors, are effective in primary and secondary prevention.
- Residual lipid risk can be addressed by targeting triglycerides, lipoprotein(a), and low HDL cholesterol levels.
- Inflammation plays a significant role in atherogenesis; anti-inflammatory therapies like colchicine and interleukin-1β inhibitors show promise.
- The review targets physicians performing coronary artery bypass grafting or percutaneous coronary intervention.
- Multiple authors report conflicts of interest, including consulting fees, grants, and stock options from various pharmaceutical companies.